High prevalence of anti-HCV antibodies in two metropolitan emergency departments in Germany: A prospective screening analysis of 28,809 patients

PLoS ONE

Volumn 7, Issue 7, 2012, Pages

  Vermehren, Johannes ^a   Schlosser, Beate ^b   Domke, Diana ^b   Elanjimattom, Sandra ^a   Müller, Christian ^b   Hintereder, Gudrun ^a   Hensel Wiegel, Karin ^b   Tauber, Rudolf ^b   Berger, Annemarie ^a   Haas, Norbert ^b   Walcher, Felix ^a   Möckel, Martin ^b   Lehmann, Ralf ^a   Zeuzem, Stefan ^a   Sarrazin, Christoph ^a   Berg, Thomas ^c  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c UNIVERSITY HOSPITAL LEIPZIG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS C VIRUS ANTIBODY; UNCLASSIFIED DRUG; VIRUS ANTIBODY; VIRUS RNA;

ARTICLE; EMERGENCY WARD; FEMALE; GERMANY; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; MAJOR CLINICAL STUDY; MALE; PREVALENCE; PROSPECTIVE STUDY; RISK FACTOR; SCREENING TEST; SEROPREVALENCE; TERTIARY HEALTH CARE;

ADULT; AGED; EMERGENCY SERVICE, HOSPITAL; FEMALE; GERMANY; HEPACIVIRUS; HEPATITIS C; HEPATITIS C ANTIBODIES; HUMANS; MALE; MASS SCREENING; MIDDLE AGED; PREVALENCE; PROSPECTIVE STUDIES; RNA, VIRAL; SEROEPIDEMIOLOGIC STUDIES;

HEPATITIS C VIRUS;

EID: 84864697158     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0041206     Document Type: Article

References (33)

1. World Health Organization (2009) Viral hepatitis: Report by the Secretariat. http://appswhoint/gb/ebwha/pdf_files/EB126/B126_15-en.pdf (accessed February 10, 2012).
2. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, et al. (2002) Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 347: 975-982.
3. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, et al. (2001) Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 358: 958-965.
4. Bacon BR, Gordon SC, Lawitz E, Marcellin P, Vierling JM, et al. (2011) Boceprevir for previously treated chronic HCV genotype 1 infection. N Engl J Med 364: 1207-1217.
5. Jacobson IM, McHutchison JG, Dusheiko G, Di Bisceglie AM, Reddy KR, et al. (2011) Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 364: 2405-2416.
6. Poordad F, McCone J Jr, Bacon BR, Bruno S, Manns MP, et al. (2011) Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med 364: 1195-1206.
7. Zeuzem S, Andreone P, Pol S, Lawitz E, Diago M, et al. (2011) Telaprevir for retreatment of HCV infection. N Engl J Med 364: 2417-2428.
8. Kau A, Vermehren J, Sarrazin C, (2008) Treatment predictors of a sustained virologic response in hepatitis B and C. J Hepatol 49: 634-651.
9. European Center for Disease Prevention and Control (2010) Hepatitis B and C in the EU neighbourhood: prevalence, burden of disease and screening policies. ECDC http://www.ecdc.europa.eu/en/publications/Publications/TER_100914_Hep_B_C%20_EU_neighbourhood.pdf (accessed February 10, 2012).
10. Cornberg M, Razavi HA, Alberti A, Bernasconi E, Buti M, et al. (2011) A systematic review of hepatitis C virus epidemiology in Europe, Canada and Israel. Liver Int 31: 30-60.
11. Palitzsch KD, Hottentrager B, Schlottmann K, Frick E, Holstege A, et al. (1999) Prevalence of antibodies against hepatitis C virus in the adult German population. Eur J Gastroenterol Hepatol 11: 1215-1220.
12. Thierfelder W, Hellenbrand W, Meisel H, Schreier E, Dortschy R, (2001) Prevalence of markers for hepatitis A, B and C in the German population. Results of the German National Health Interview and Examination Survey 1998. Eur J Epidemiol 17: 429-435.
13. Robert Koch Institute (2011) Zur Situation bei wichtigen Infektionskrankheiten in Deutschland: Virushepatitis B, C und D im Jahr 2010. Epidemiologisches Bulletin 29: 261-271.
14. Sarrazin C, Berg T, Ross RS, Schirmacher P, Wedemeyer H, et al. (2010) [Prophylaxis, diagnosis and therapy of hepatitis C virus (HCV) infection: the German guidelines on the management of HCV infection]. Z Gastroenterol 48: 289-351.
15. Rosen HR, (2011) Clinical practice. Chronic hepatitis C infection. N Engl J Med 364: 2429-2438.
16. Bacon BR, (2002) Treatment of patients with hepatitis C and normal serum aminotransferase levels. Hepatology 36: S179-184.
17. Zeuzem S, Diago M, Gane E, Reddy KR, Pockros P, et al. (2004) Peginterferon alfa-2a (40 kilodaltons) and ribavirin in patients with chronic hepatitis C and normal aminotransferase levels. Gastroenterology 127: 1724-1732.
18. Conry-Cantilena C, VanRaden M, Gibble J, Melpolder J, Shakil AO, et al. (1996) Routes of infection, viremia, and liver disease in blood donors found to have hepatitis C virus infection. N Engl J Med 334: 1691-1696.
19. Hüppe D, Zehnter E, Mauss S, Boker K, Lutz T, et al. (2008) [Epidemiology of chronic hepatitis C in Germany-an analysis of 10,326 patients in hepatitis centers and outpatient units]. Z Gastroenterol 46: 34-44.
20. Wiegand J, Luz B, Mengelkamp AK, Moog R, Koscielny J, et al. (2009) Autologous blood donor screening indicated a lower prevalence of viral hepatitis in East vs West Germany: epidemiological benefit from established health resources. J Viral Hepat 16: 743-748.
21. Alborino F, Burighel A, Tiller FW, van Helden J, Gabriel C, et al. (2011) Multicenter evaluation of a fully automated third-generation anti-HCV antibody screening test with excellent sensitivity and specificity. Med Microbiol Immunol 200: 77-83.
22. Kim S, Kim JH, Yoon S, Park YH, Kim HS, (2008) Clinical performance evaluation of four automated chemiluminescence immunoassays for hepatitis C virus antibody detection. J Clin Microbiol 46: 3919-3923.
23. Kelen GD, Green GB, Purcell RH, Chan DW, Qaqish BF, et al. (1992) Hepatitis B and hepatitis C in emergency department patients. N Engl J Med 326: 1399-1404.
24. Russmann S, Dowlatshahi EA, Printzen G, Habicht S, Reichen J, et al. (2007) Prevalence and associated factors of viral hepatitis and transferrin elevations in 5036 patients admitted to the emergency room of a Swiss university hospital: cross-sectional study. BMC Gastroenterol 7: 5.
25. Hoofnagle JH, Mullen KD, Jones DB, Rustgi V, Di Bisceglie A, et al. (1986) Treatment of chronic non-A, non-B hepatitis with recombinant human alpha interferon. A preliminary report. N Engl J Med 315: 1575-1578.
26. Delarocque-Astagneau E, Meffre C, Dubois F, Pioche C, Le Strat Y, et al. (2010) The impact of the prevention programme of hepatitis C over more than a decade: the French experience. J Viral Hepat 17: 435-443.
27. McHutchison JG, Bacon BR, (2005) Chronic hepatitis C: an age wave of disease burden. Am J Manag Care 11: S286-295; quiz S307-311.
28. Shatin D, Schech SD, Patel K, McHutchison JG, (2004) Population-based hepatitis C surveillance and treatment in a national managed care organization. Am J Manag Care 10: 250-256.
29. Caspari G, Gerlich WH, Beyer J, Schmitt H, (1995) Age, sex and transaminase dependency of specific and nonspecific results from enzyme immunoassays for antibodies to hepatitis C virus and follow-up of blood donors. Infusionsther Transfusionsmed 22: 208-219.
30. Danta M, Brown D, Bhagani S, Pybus OG, Sabin CA, et al. (2007) Recent epidemic of acute hepatitis C virus in HIV-positive men who have sex with men linked to high-risk sexual behaviours. AIDS 21: 983-991.
31. Schmidt AJ, Rockstroh JK, Vogel M, An der Heiden M, Baillot A, et al. (2011) Trouble with bleeding: risk factors for acute hepatitis C among HIV-positive gay men from Germany-a case-control study. PLoS One 6: e17781.
32. van de Laar TJ, Matthews GV, Prins M, Danta M, (2010) Acute hepatitis C in HIV-infected men who have sex with men: an emerging sexually transmitted infection. AIDS 24: 1799-1812.
33. McGarry LJ, Pawar VS, Parekh HH, Rubin JL, Davis GL, et al. (2012) Economic model of a birth cohort screening program for hepatitis C virus. Hepatology 55: 1344-1355.